ArticleFrontiers in pharmacology2025
Exploratory analysis of non-linear clozapine dose-concentration relationship in real-life hospital database.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Clozapine (CLO) remains the gold standard for the treatment of drug-resistant schizophrenia. It is commonly accepted that there is a linear relationship between CLO dose and blood concentration, although deviations from this pattern are frequently observed in clinical practice. The aim of the present naturalistic study was to further investigate this relationship using a real-world database of CLO therapeutic drug monitoring (TDM) samples, with a particular focus on: i) identifying cases of "unexpected" CLO levels during repeated within-subject blood sampling in the process of CLO dose adjustment and ii) assessing linearity of the cross-sectional, between-subject CLO dose-concentration relationship and identifying potential breakpoints. Methods: The study was based on a single-center TDM database derived from routine monitoring of CLO concentration in psychiatric inpatients, supplemented with data from medical records. The database was reviewed independently by a laboratory medicine specialist and psychiatrist to identify individual cases of "unanticipated" dose-concentration relationships. The study also employed the Multivariate Adaptive Regression Splines (MARS) to detect non-linear relationships in the prediction of CLO levels, as determined by high-performance liquid chromatography. Analyses incorporated variables such as daily CLO dose, smoking status, age, sex, and co-medications. Results: Individual cases of "unanticipated" CLO concentrations supporting the partially non-linear within-subject dose-concentration relationship were unambiguously identified by both specialists. The MARS model revealed a breakdown in the between-subject CLO dose-concentration linear relationship identifying a hinge point around 400 mg/day, below which CLO concentrations were less dose-dependent. CLO dose and smoking were the most important predictive factors, but the model explained only about 25% of CLO concentration variability. Conclusion: Our data suggest that the non-linear relationship between CLO concentration and its daily dose can be a real-life clinical problem with CLO doses of ∼400 mg/day as the provisional hinge point. Although preliminary, the present results warrant further investigations on non-linear aspects of CLO pharmacology, including "unexpected" CLO concentrations, toxicity, and lack of therapeutic activity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.